methylphenidate hydrochloride

FDA Drug Profile — methylphenidate hydrochloride CD, METADATE CD, QuilliChew ER, Ritalin, Methylphenidate Hydrochloride Extended-Release

methylphenidate hydrochloride is listed in the FDA National Drug Code directory with 50 NDC codes, marketed under brand names including methylphenidate hydrochloride CD, METADATE CD, QuilliChew ER. Available dosage forms: capsule, extended release, tablet, chewable, extended release, tablet, tablet, extended release, suspension, extended release.

Drug Details

Generic Name
methylphenidate hydrochloride
Brand Names
methylphenidate hydrochloride CD, METADATE CD, QuilliChew ER, Ritalin, Methylphenidate Hydrochloride Extended-Release, RELEXXII, Ritalin LA, Quillivant XR, methylphenidate hydrochloride
Application Number
NDA021259
Sponsor
Lannett Company, LLC
NDC Codes
50
Dosage Forms
CAPSULE, EXTENDED RELEASE, TABLET, CHEWABLE, EXTENDED RELEASE, TABLET, TABLET, EXTENDED RELEASE, SUSPENSION, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of methylphenidate hydrochloride extended-release tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), and Use in Specific Populations ( 8.4 )]. Methylphenidate hydrochloride extended-release tablets are a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old ( 1 ). Limitations of Use The use of methylphenidate hydrochloride extended-release tablets are not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).